Indivior Plc
Indivior Plc specializes in the development of medications for the treatment of addictions and related disorders.
Price history of Indivior Plc
Price history of Indivior Plc
Performance & Momentum
Indivior Projects Strong $1.125-$1.195B Revenue in 2026
Indivior Plc, listed on NASDAQ under INDV, released its 2026 financial guidance, forecasting total revenue between $1.125 billion and $1.195 billion. This outlook is largely driven by robust expected sales of SUBLOCADE®, estimated at $905 million to $945 million, reflecting the company's strong commercial momentum. Despite recent stock price consolidation, the long-term performance remains highly favorable, underpinning investor optimism about growth prospects.
Strategic Analysis
Indivior Plc • 2026
Indivior is a niche pharmaceutical company specializing in addiction treatments, with a focus on opioid-related disorders. Its business model is built on high-clinical-value medicines in a sensitive therapeutic area, where regulatory expertise, market access, and scientific credibility provide real competitive advantages.
- Defensive positioning in a specialized therapeutic area with structural demand linked to the opioid crisis
- Focused portfolio of treatments with strong clinical differentiation and high regulatory barriers
- Very strong recent stock price momentum, reflecting a marked resurgence in market confidence
- Dependence on a therapeutic niche exposed to regulatory, legal, and reputational risks
- Business model concentrated in a narrow segment, limiting diversification
Momentum is exceptionally strong and reflects a firmly established upward trend, with sustained buying interest across multiple time horizons. This profile suggests that execution is perceived as robust and that the re-rating is already well advanced, but it also implies a heightened sensitivity to any operational, regulatory, or competitive disappointment.
Similar stocks to Indivior Plc
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
